FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053412372> ?p ?o ?g. }

• W2053412372 endingPage "1381" @default.
• W2053412372 startingPage "1376" @default.
• W2053412372 abstract "BackgroundIn this study, we analyzed the usefulness of adjuvant chemotherapy for non-small cell lung cancer based on the histoculture drug response assay (HDRA).MethodsFrom September 2001 to December 2008, 65 patients with pathologic stage II or higher non-small cell lung cancer who underwent surgery received two-cycle HDRA-based adjuvant chemotherapy. Chemosensitivity to cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine, and irinotecan was examined by the HDRA. All patients were classified according to the number of administered HDRA-positive drugs: the prediction-sensitive group (PSG) (n = 31) comprised patients treated with two HDRA-positive drugs and the prediction-nonsensitive group (PNSG) (n = 34) comprised those treated with a combination of one HDRA-positive and one HDRA-negative drug or two HDRA-negative drugs. The clinical outcomes of the two groups were analyzed.ResultsThe overall 5-year survival rate of the PSG was 82.4%. On the other hand, that of the PNSG was 40.1%. There were significant differences between the two groups (p = 0.03). The 5-year disease-free survival rate was more favorable in the PSG than in the PNSG (PSG: 56.5%, PNSG: 30.1%, p = 0.05). Multivariate analysis showed that chemotherapy based on the HDRA was a significant prognostic factor (p = 0.03).ConclusionsThe prognosis of patients treated with two HDRA-positive drugs was significantly better than that of those treated with one HDRA-positive drug or HDRA-negative drugs. Adjuvant chemotherapy based on the in vitro HDRA may be useful to improve survival in patients who have undergone surgery. In this study, we analyzed the usefulness of adjuvant chemotherapy for non-small cell lung cancer based on the histoculture drug response assay (HDRA). From September 2001 to December 2008, 65 patients with pathologic stage II or higher non-small cell lung cancer who underwent surgery received two-cycle HDRA-based adjuvant chemotherapy. Chemosensitivity to cisplatin, carboplatin, paclitaxel, docetaxel, gemcitabine, and irinotecan was examined by the HDRA. All patients were classified according to the number of administered HDRA-positive drugs: the prediction-sensitive group (PSG) (n = 31) comprised patients treated with two HDRA-positive drugs and the prediction-nonsensitive group (PNSG) (n = 34) comprised those treated with a combination of one HDRA-positive and one HDRA-negative drug or two HDRA-negative drugs. The clinical outcomes of the two groups were analyzed. The overall 5-year survival rate of the PSG was 82.4%. On the other hand, that of the PNSG was 40.1%. There were significant differences between the two groups (p = 0.03). The 5-year disease-free survival rate was more favorable in the PSG than in the PNSG (PSG: 56.5%, PNSG: 30.1%, p = 0.05). Multivariate analysis showed that chemotherapy based on the HDRA was a significant prognostic factor (p = 0.03). The prognosis of patients treated with two HDRA-positive drugs was significantly better than that of those treated with one HDRA-positive drug or HDRA-negative drugs. Adjuvant chemotherapy based on the in vitro HDRA may be useful to improve survival in patients who have undergone surgery." @default.
• W2053412372 created "2016-06-24" @default.
• W2053412372 creator A5008838011 @default.
• W2053412372 creator A5013252301 @default.
• W2053412372 creator A5015347008 @default.
• W2053412372 creator A5029949387 @default.
• W2053412372 creator A5059047023 @default.
• W2053412372 creator A5060983596 @default.
• W2053412372 date "2010-09-01" @default.
• W2053412372 modified "2023-09-30" @default.
• W2053412372 title "Adjuvant Chemotherapy Based on the In Vitro Histoculture Drug Response Assay for Non-small Cell Lung Cancer Improves Survival" @default.
• W2053412372 cites W1797421894 @default.
• W2053412372 cites W189287319 @default.
• W2053412372 cites W1967802960 @default.
• W2053412372 cites W1971972686 @default.
• W2053412372 cites W1979021710 @default.
• W2053412372 cites W1994716931 @default.
• W2053412372 cites W2000683063 @default.
• W2053412372 cites W2003549930 @default.
• W2053412372 cites W2012691123 @default.
• W2053412372 cites W2013926406 @default.
• W2053412372 cites W2015382854 @default.
• W2053412372 cites W2017256577 @default.
• W2053412372 cites W2021292361 @default.
• W2053412372 cites W2053095296 @default.
• W2053412372 cites W2077703128 @default.
• W2053412372 cites W2086955530 @default.
• W2053412372 cites W2102026830 @default.
• W2053412372 cites W2105007385 @default.
• W2053412372 cites W2117994949 @default.
• W2053412372 cites W2120819664 @default.
• W2053412372 cites W2127342594 @default.
• W2053412372 cites W2133104419 @default.
• W2053412372 cites W2148809157 @default.
• W2053412372 cites W2158234609 @default.
• W2053412372 cites W2171443545 @default.
• W2053412372 cites W2250103185 @default.
• W2053412372 doi "https://doi.org/10.1097/jto.0b013e3181e7d035" @default.
• W2053412372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34883556" @default.
• W2053412372 hasPublicationYear "2010" @default.
• W2053412372 type Work @default.
• W2053412372 sameAs 2053412372 @default.
• W2053412372 citedByCount "4" @default.
• W2053412372 countsByYear W20534123722017 @default.
• W2053412372 countsByYear W20534123722021 @default.
• W2053412372 countsByYear W20534123722023 @default.
• W2053412372 crossrefType "journal-article" @default.
• W2053412372 hasAuthorship W2053412372A5008838011 @default.
• W2053412372 hasAuthorship W2053412372A5013252301 @default.
• W2053412372 hasAuthorship W2053412372A5015347008 @default.
• W2053412372 hasAuthorship W2053412372A5029949387 @default.
• W2053412372 hasAuthorship W2053412372A5059047023 @default.
• W2053412372 hasAuthorship W2053412372A5060983596 @default.
• W2053412372 hasBestOaLocation W20534123721 @default.
• W2053412372 hasConcept C126322002 @default.
• W2053412372 hasConcept C2776256026 @default.
• W2053412372 hasConcept C2776694085 @default.
• W2053412372 hasConcept C2777863537 @default.
• W2053412372 hasConcept C2780035454 @default.
• W2053412372 hasConcept C2781190966 @default.
• W2053412372 hasConcept C2994119904 @default.
• W2053412372 hasConcept C71924100 @default.
• W2053412372 hasConcept C98274493 @default.
• W2053412372 hasConceptScore W2053412372C126322002 @default.
• W2053412372 hasConceptScore W2053412372C2776256026 @default.
• W2053412372 hasConceptScore W2053412372C2776694085 @default.
• W2053412372 hasConceptScore W2053412372C2777863537 @default.
• W2053412372 hasConceptScore W2053412372C2780035454 @default.
• W2053412372 hasConceptScore W2053412372C2781190966 @default.
• W2053412372 hasConceptScore W2053412372C2994119904 @default.
• W2053412372 hasConceptScore W2053412372C71924100 @default.
• W2053412372 hasConceptScore W2053412372C98274493 @default.
• W2053412372 hasIssue "9" @default.
• W2053412372 hasLocation W20534123721 @default.
• W2053412372 hasLocation W20534123722 @default.
• W2053412372 hasOpenAccess W2053412372 @default.
• W2053412372 hasPrimaryLocation W20534123721 @default.
• W2053412372 hasRelatedWork W2032912323 @default.
• W2053412372 hasRelatedWork W2080820783 @default.
• W2053412372 hasRelatedWork W2157582460 @default.
• W2053412372 hasRelatedWork W2315587357 @default.
• W2053412372 hasRelatedWork W2360684383 @default.
• W2053412372 hasRelatedWork W2390152934 @default.
• W2053412372 hasRelatedWork W2403259785 @default.
• W2053412372 hasRelatedWork W2405923032 @default.
• W2053412372 hasRelatedWork W2575007916 @default.
• W2053412372 hasRelatedWork W3029039913 @default.
• W2053412372 hasVolume "5" @default.
• W2053412372 isParatext "false" @default.
• W2053412372 isRetracted "false" @default.
• W2053412372 magId "2053412372" @default.
• W2053412372 workType "article" @default.